Comparison of Mac‐2 binding protein glycosylation isomer ( <scp>M2BPGi</scp> ) with <scp>AST</scp> to platelet ratio index ( <scp>APRI</scp> ), fibrosis 4 Score ( <scp>FIB</scp> ‐4), and nonalcoholic fatty liver disease ( <scp>NAFLD</scp> ) fibrosis score ( <scp>NFS</scp> ) for <scp>NAFLD</scp> patients-Reference-Cited by-同舟云学术

Comparison of Mac‐2 binding protein glycosylation isomer ( M2BPGi ) with AST to platelet ratio index ( APRI ), fibrosis 4 Score ( FIB ‐4), and nonalcoholic fatty liver disease ( NAFLD ) fibrosis score ( NFS ) for NAFLD patients

Published:2022-07-05 Issue: Volume: Page:
ISSN:2351-9797
Container-title:Advances in Digestive Medicine
language:en
Short-container-title:Adv in Digestive Medicine

Author:

Cheng Yu‐Ming¹^ORCID,Wang Chia‐Chi¹²

Affiliation:

1. Department of Gastroenterology, Taipei Tzu Chi Hospital Buddhist Tzu Chi Medical Foundation Taipei Taiwan

2. School of Medicine Tzu Chi University Hualien Taiwan

Funder

Taipei Tzu Chi Hospital

Publisher

Wiley

Subject

Gastroenterology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/aid2.13315

Reference32 articles.

1. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

2. Nonalcoholic fatty liver disease: From steatosis to cirrhosis

3. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance

4. Role of liver biopsy in management of chronic hepatitis C: A systematic review

5. Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why liver biopsy is essential

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisiting Mac-2-Binding Protein Glycosylation Isomer (M2BPGi) for Diagnosing High-Risk Liver Fibrosis in Chronic Hepatitis B Patients: A Stepwise Diagnostic Analysis;F1000Research;2024-07-12

2. Revisiting Mac-2-Binding Protein Glycosylation Isomer (M2BPGi) for Diagnosing High-Risk Liver Fibrosis: A Stepwise Diagnostic Analysis;F1000Research;2024-04-16

3. Noninvasive disease severity assessment in nonalcoholic fatty liver disease;Advances in Digestive Medicine;2023-06